A Critical Analysis of the Clinical Use of Incretin-Based Therapies: The benefits by far outweigh the potential risks

by Nauck, Michael A.
Published 2013

Update on developments with SGLT2 inhibitors in the management of type 2 diabetes

by Nauck, Michael A
Published 2014

Do GLP-1–Based Therapies Increase Cancer Risk?

by Nauck, Michael A., Friedrich, Nele
Published 2013

Comparative evaluation of incretin‐based antidiabetic medications and alternative therapies to be added to metformin in the case of monotherapy failure†

by Nauck, Michael A, Vardarli, Irfan
Published 2010

Chronic Reduction of Fasting Glycemia With Insulin Glargine Improves First- and Second-Phase Insulin Secretion in Patients With Type 2 Diabetes

by Pennartz, Christian, Schenker, Nina, Menge, Björn A., Schmidt, Wolfgang E., Nauck, Michael A., Meier, Juris J.
Published 2011

Rapid Tachyphylaxis of the Glucagon-Like Peptide 1–Induced Deceleration of Gastric Emptying in Humans

by Nauck, Michael A., Kemmeries, Guido, Holst, Jens J., Meier, Juris J.
Published 2011

Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin: A randomized, 52-week, double-blind, active-c...

by Nauck, Michael A., Del Prato, Stefano, Meier, Juris J., Durán-García, Santiago, Rohwedder, Katja, Elze, Martina, Parikh, Shamik J.
Published 2011

Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with typ...

by Nauck, Michael A., Stewart, Murray W., Perkins, Christopher, Jones-Leone, Angela, Yang, Fred, Perry, Caroline, Reinhardt, Rickey R., Rendell, Marc
Published 2015

GIP Does Not Potentiate the Antidiabetic Effects of GLP-1 in Hyperglycemic Patients With Type 2 Diabetes

by Mentis, Nikolaos, Vardarli, Irfan, Köthe, Lars D., Holst, Jens J., Deacon, Carolyn F., Theodorakis, Michael, Meier, Juris J., Nauck, Michael A.
Published 2011

Efficacy and Safety of Switching From the DPP-4 Inhibitor Sitagliptin to the Human GLP-1 Analog Liraglutide After 52 Weeks in Metformin-Treated Patients With Type 2 Diabetes: A ran...

by Pratley, Richard E., Nauck, Michael A., Bailey, Timothy, Montanya, Eduard, Filetti, Sebastiano, Garber, Alan J., Thomsen, Anne B., Furber, Sabina, Davies, Melanie
Published 2012

Beyond Metformin: Safety Considerations in the Decision-Making Process for Selecting a Second Medication for Type 2 Diabetes Management: Reflections From a Diabetes Care Editors’ E...

by Cefalu, William T., Buse, John B., Del Prato, Stefano, Home, Philip D., LeRoith, Derek, Nauck, Michael A., Raz, Itamar, Rosenstock, Julio, Riddle, Matthew C.
Published 2014

Effects of glucose-dependent insulinotropic polypeptide on gastric emptying, glycaemia and insulinaemia during critical illness: a prospective, double blind, randomised, crossover...

by Kar, Palash, Cousins, Caroline E, Annink, Christopher E, Jones, Karen L, Chapman, Marianne J, Meier, Juris J, Nauck, Michael A, Horowitz, Michael, Deane, Adam M
Published 2015

Comparative Effects of Prolonged and Intermittent Stimulation of the Glucagon-Like Peptide 1 Receptor on Gastric Emptying and Glycemia

by Umapathysivam, Mahesh M., Lee, Michael Y., Jones, Karen L., Annink, Christopher E., Cousins, Caroline E., Trahair, Laurence G., Rayner, Chris K., Chapman, Marianne J., Nauck, Michael A., Horowitz, Michael, Deane, Adam M.
Published 2014

LEADER 3—Lipase and Amylase Activity in Subjects With Type 2 Diabetes: Baseline Data From Over 9000 Subjects in the LEADER Trial

by Steinberg, William M., Nauck, Michael A., Zinman, Bernard, Daniels, Gilbert H., Bergenstal, Richard M., Mann, Johannes F.E., Steen Ravn, Lasse, Moses, Alan C., Stockner, Mette, Baeres, Florian M.M., Marso, Steven P., Buse, John B.
Published 2014